These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9094110)

  • 1. Genentech and IDEC await approval of lymphoma Mab.
    Nat Biotechnol; 1997 Apr; 15(4):301. PubMed ID: 9094110
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA approves new kind of lymphoma treatment. Food and Drug Administration.
    James JS; Dubs G
    AIDS Treat News; 1997 Dec; (No 284):2-3. PubMed ID: 11364912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoma Mabs rivalry continues.
    Webber D
    Nat Biotechnol; 1998 Nov; 16(11):1000-1. PubMed ID: 9831017
    [No Abstract]   [Full Text] [Related]  

  • 4. Off-label uses of monoclonal antibodies for treatment of B-cell lymphoid or myeloid malignancies.
    Tecnologica MAP Suppl; 2001 Jul; ():14-7. PubMed ID: 11718149
    [No Abstract]   [Full Text] [Related]  

  • 5. Lymphoma treatment approved.
    AIDS Patient Care STDS; 1998 Mar; 12(3):231. PubMed ID: 11361944
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal antibody successes in the clinic.
    Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
    Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab in indolent lymphoma: the single-agent pivotal trial.
    McLaughlin P; Hagemeister FB; Grillo-López AJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):79-87. PubMed ID: 10561022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A piece of history.
    Nat Biotechnol; 2003 Aug; 21(8):831. PubMed ID: 12894179
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [First monoclonal antibody accepted for cancer therapy].
    Itälä M
    Duodecim; 1998; 114(6):509, 511. PubMed ID: 11466914
    [No Abstract]   [Full Text] [Related]  

  • 13. PDL's mAb technology finds right timing.
    Fletcher L
    Nat Biotechnol; 2001 May; 19(5):395-6. PubMed ID: 11328982
    [No Abstract]   [Full Text] [Related]  

  • 14. Newer monoclonal antibodies for hematological malignancies.
    Castillo J; Winer E; Quesenberry P
    Exp Hematol; 2008 Jul; 36(7):755-68. PubMed ID: 18565392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-1 trap go-ahead.
    Ratner M
    Nat Biotechnol; 2008 May; 26(5):485. PubMed ID: 18464767
    [No Abstract]   [Full Text] [Related]  

  • 16. Fast track for antiretroviral.
    AIDS Patient Care STDS; 2003 Dec; 17(12):665. PubMed ID: 14750222
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment for wet macular degeneration.
    FDA Consum; 2006; 40(5):6. PubMed ID: 17326303
    [No Abstract]   [Full Text] [Related]  

  • 18. Fast track to MS drug.
    Sheridan C
    Nat Biotechnol; 2004 Aug; 22(8):939-41. PubMed ID: 15286635
    [No Abstract]   [Full Text] [Related]  

  • 19. A new approach for MS.
    Morrow T
    Manag Care; 2005 Jan; 14(1):85-7. PubMed ID: 15742758
    [No Abstract]   [Full Text] [Related]  

  • 20. MS drug back on market under restricted program.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17243280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.